Osimertinib (Tagrisso,Oysiendx)

Osimertinib is a third-generation targeted therapy for lung cancer, specifically designed to treat non-small cell lung cancer driven by specific genetic mutations.

80mg*30tablets

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Osimertinib Drug News

Tagrisso (Osimertinib) Approved in the UK for Two Lung Cancer Indications

Last Friday, the UK's National Institute for Health and Care Evaluation (NICE) reversed its earlier rejection of AstraZeneca's lung cancer the···【More】
Update: 23 Mar,2026Source: BigbearViews: 101
Tagrisso in combination with chemotherapy has been approved in the United States

AstraZeneca recently announced that its supplemental New Drug Application (sNDA) for Tagrisso (osimertinib), an epidermal growth factor receptor (EGFR···【More】
Update: 23 Mar,2026Source: BigbearViews: 93
TAGRISSO (Osimertinib) Drug Guidelines

The U.S. Food and Drug Administration (FDA) has approved TAGRISSO (osimertinib) for first-line treatment of patients with metastatic non-small cell lu···【More】
Update: 23 Mar,2026Source: BigbearViews: 98
Tagrisso Approved for New Indication: Treatment of Stage III Unresectable EGFR-Mutant NSCLC

AstraZeneca announced yesterday that the U.S. Food and Drug Administration (FDA) has approved its epidermal growth factor receptor (EGFR) tyrosine kin···【More】
Update: 23 Mar,2026Source: BigbearViews: 93